Poland · Delayed Price · Currency is PLN Biogened Statistics
Total Valuation
Biogened has a market cap or net worth of PLN 51.09 million. The enterprise value is 73.13 million.
| Market Cap | 51.09M |
| Enterprise Value | 73.13M |
Important Dates
The next confirmed earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | Sep 10, 2026 |
Share Statistics
Biogened has 2.46 million shares outstanding.
| Current Share Class | 2.46M |
| Shares Outstanding | 2.46M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 1.03% |
| Float | 144,714 |
Valuation Ratios
The trailing PE ratio is 10.50.
| PE Ratio | 10.50 |
| Forward PE | n/a |
| PS Ratio | 0.47 |
| PB Ratio | 1.08 |
| P/TBV Ratio | 1.13 |
| P/FCF Ratio | 14.62 |
| P/OCF Ratio | 4.46 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.26, with an EV/FCF ratio of 20.93.
| EV / Earnings | 15.02 |
| EV / Sales | 0.67 |
| EV / EBITDA | 5.26 |
| EV / EBIT | 7.67 |
| EV / FCF | 20.93 |
Financial Position
The company has a current ratio of 1.93, with a Debt / Equity ratio of 0.62.
| Current Ratio | 1.93 |
| Quick Ratio | 1.17 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | 2.10 |
| Debt / FCF | 8.35 |
| Interest Coverage | 4.59 |
Financial Efficiency
Return on equity (ROE) is 10.86% and return on invested capital (ROIC) is 9.47%.
| Return on Equity (ROE) | 10.86% |
| Return on Assets (ROA) | 6.25% |
| Return on Invested Capital (ROIC) | 9.47% |
| Return on Capital Employed (ROCE) | 14.30% |
| Weighted Average Cost of Capital (WACC) | 5.17% |
| Revenue Per Employee | 595,071 |
| Profits Per Employee | 26,453 |
| Employee Count | 184 |
| Asset Turnover | 1.17 |
| Inventory Turnover | 1.60 |
Taxes
In the past 12 months, Biogened has paid 2.40 million in taxes.
| Income Tax | 2.40M |
| Effective Tax Rate | 33.00% |
Stock Price Statistics
The stock price has decreased by -20.61% in the last 52 weeks. The beta is 0.21, so Biogened's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | -20.61% |
| 50-Day Moving Average | 19.11 |
| 200-Day Moving Average | 21.80 |
| Relative Strength Index (RSI) | 70.20 |
| Average Volume (20 Days) | 72 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biogened had revenue of PLN 109.49 million and earned 4.87 million in profits. Earnings per share was 1.98.
| Revenue | 109.49M |
| Gross Profit | 71.23M |
| Operating Income | 9.34M |
| Pretax Income | 7.26M |
| Net Income | 4.87M |
| EBITDA | 13.91M |
| EBIT | 9.53M |
| Earnings Per Share (EPS) | 1.98 |
Balance Sheet
The company has 7.13 million in cash and 29.18 million in debt, with a net cash position of -22.04 million or -8.97 per share.
| Cash & Cash Equivalents | 7.13M |
| Total Debt | 29.18M |
| Net Cash | -22.04M |
| Net Cash Per Share | -8.97 |
| Equity (Book Value) | 47.25M |
| Book Value Per Share | 19.24 |
| Working Capital | 27.11M |
Cash Flow
In the last 12 months, operating cash flow was 11.45 million and capital expenditures -7.96 million, giving a free cash flow of 3.49 million.
| Operating Cash Flow | 11.45M |
| Capital Expenditures | -7.96M |
| Depreciation & Amortization | 4.61M |
| Net Borrowing | -71,760 |
| Free Cash Flow | 3.49M |
| FCF Per Share | 1.42 |
Margins
Gross margin is 65.05%, with operating and profit margins of 8.53% and 4.45%.
| Gross Margin | 65.05% |
| Operating Margin | 8.53% |
| Pretax Margin | 6.63% |
| Profit Margin | 4.45% |
| EBITDA Margin | 12.19% |
| EBIT Margin | 8.36% |
| FCF Margin | 3.19% |
Dividends & Yields
This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 2.40%.
| Dividend Per Share | 0.50 |
| Dividend Yield | 2.40% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 25.23% |
| Buyback Yield | n/a |
| Shareholder Yield | 2.40% |
| Earnings Yield | 9.53% |
| FCF Yield | 6.84% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Biogened has an Altman Z-Score of 2.64 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.64 |
| Piotroski F-Score | 5 |